BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 14, 2005
 |  BioCentury  |  Strategy

Feeling no pain with $150M

There's no shortage of opioid painkillers on the market and in development, but there's still a lot of money to be made with novel delivery techniques. A case in point is Pain Therapeutics Inc., which last week received $150 million up front when it partnered its Remoxy sustained-release oxycontin and three undisclosed opioid painkillers with King Pharmaceuticals Inc.

The key, according to PTIE, is to solve a fundamental problem for opioids - the potential for abuse. The partners are betting that Remoxy will capture market share by winning primary care physicians who are reluctant to prescribe opioids because of the abuse risks. PTIE (South San Francisco, Calif.) and KG (Bristol, Tenn.) hope Remoxy's sustained-release gel-cap formulation will hinder would-be abusers.

The 800-pound gorilla in the pain space is OxyContin oxycodone CR from Purdue Pharma L.P. (Stamford, Conn.). Purdue doesn't publish its sales, but according to Remi Barbier, president and...

Read the full 755 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >